Precigen Inc (PGEN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Precigen Inc (PGEN) has a cash flow conversion efficiency ratio of -1.122x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-23.46 Million) by net assets ($20.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Precigen Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Precigen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read PGEN total liabilities for a breakdown of total debt and financial obligations.
Precigen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Precigen Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Huludao Zinc Industry Co Ltd
SHE:000751
|
0.111x |
|
Fujian Dongbai Group Co Ltd
SHG:600693
|
0.037x |
|
IGNITIS GRUPE SP.GDR/1
F:IGV
|
N/A |
|
Custom Truck One Source Inc
NYSE:CTOS
|
0.156x |
|
Kimbell Royalty Partners LP
NYSE:KRP
|
0.080x |
|
New Guomai Digital Culture Co Ltd
SHG:600640
|
0.019x |
|
Arlo Technologies
NYSE:ARLO
|
0.155x |
|
AtriCure Inc
NASDAQ:ATRC
|
0.056x |
Annual Cash Flow Conversion Efficiency for Precigen Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Precigen Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Precigen Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $20.91 Million | $-87.83 Million | -4.200x | -137.28% |
| 2024-12-31 | $38.51 Million | $-68.17 Million | -1.770x | -213.40% |
| 2023-12-31 | $118.50 Million | $-66.93 Million | -0.565x | -9.64% |
| 2022-12-31 | $126.26 Million | $-65.05 Million | -0.515x | +0.84% |
| 2021-12-31 | $107.35 Million | $-55.77 Million | -0.520x | +54.69% |
| 2020-12-31 | $67.17 Million | $-77.02 Million | -1.147x | -6.75% |
| 2019-12-31 | $71.71 Million | $-77.02 Million | -1.074x | -227.40% |
| 2018-12-31 | $378.72 Million | $-124.24 Million | -0.328x | -72.17% |
| 2017-12-31 | $546.54 Million | $-104.14 Million | -0.191x | -93.77% |
| 2016-12-31 | $569.25 Million | $-55.98 Million | -0.098x | -294.32% |
| 2015-12-31 | $704.89 Million | $35.67 Million | 0.051x | +204.30% |
| 2014-12-31 | $409.29 Million | $-19.86 Million | -0.049x | +65.53% |
| 2013-12-31 | $381.34 Million | $-53.68 Million | -0.141x | -173.57% |
| 2012-12-31 | $-321.55 Million | $-61.53 Million | 0.191x | -48.22% |
| 2011-12-31 | $-221.26 Million | $-81.76 Million | 0.370x | -- |
About Precigen Inc
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors… Read more